Blog
Featured post
Truveta Data includes linked closed claims for over 200 million patients
By linking complete clinical data with comprehensive claims records, Truveta advances real-world evidence (RWE) generation that can replace, or complement, clinical trials and registries.
Exploring medication switching trends from Humira to approved biosimilars
Authors: Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA,...
Improving ovarian cancer outcomes with EHR data
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the...
Scaling AI models for growth
In this blog I will discuss our approach to scaling our AI technologies across multiple dimensions while controlling development costs, operational costs, and assuring stability....
Truveta Research leads first study to explore GLP-1 reinitiation trends and factors
This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication...
Trends in testing and diagnosis of peripheral vascular disease in the US
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first...
GLP-1 RA prescription trends: January 2018 – June 2024
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2024 increased slightly relative to March 2024 (+8.43%). Month-over-month anti-diabetic...
Truveta Symposium brings together healthcare, public health, and life science organizations with a shared mission of Saving Lives with Data
Today, Truveta kicks off Truveta Symposium, a unique event bringing together leaders from health systems, life sciences, and the government to collaborate on health research with...
Real-world data study comparing Mounjaro and Ozempic for weight loss published in JAMA Internal Medicine
Truveta Research's comparative effectiveness study exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro) has been published in JAMA...
Truveta Data used in new study finds increased use of CGM in patients with type 2 diabetes initiating GLP-1 medications
Citation Wang X, Xu Y, Norman G, et al. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data. Diabetes. June 14, 2024....